Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.
BACKGROUND
Although many treatment modalities have been tried for the treatment of vitiligo, none is uniformly effective. Psoralen phototherapy (psoralen ultraviolet A (PUVA)) is established as efficacious treatment for vitiligo. Recently, narrow-band UVB (NBUVB) has been reported to be an effective and safe therapeutic option in patients with vitiligo.


OBJECTIVE
To compare the efficacy of PUVA and NBUVB in the treatment of vitiligo.


METHODS
Retrospective analysis of 69 patients with vitiligo who were treated either with PUVA or NBUVB at the pigmentary clinic of the Dermatology Department of the Postgraduate Institute of Medical Education and Research, Chandigarh, India.


METHODS
The following variables were compared between the two groups of patients: repigmentation status, number of treatments for marked to complete repigmentation in existing lesions, appearance of new lesions or increase in size of existing lesions, adverse effect of therapy, stability of repigmentation and colour match.


RESULTS
In PUVA-treated group, 9 patients showed marked to complete repigmentation (23.6%) and 14 patients showed moderate improvement (36.8%), whereas in NBUVB-treated group, 13 patients showed marked to complete repigmentation (41.9%) and 10 patients showed moderate improvement (32.2%). A statistically significantly better stability and colour match of repigmentation with surrounding skin was seen in NBUVB-treated patients.


CONCLUSIONS
We showed that NBUVB is more effective than PUVA and repigmentation induced with NBUVB is statistically significantly more stable.
Parsad
D
D
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education & Research, Chandigarh, India. dprs@satyam.net.in
Kanwar
A J
AJ
Kumar
B
B
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011701:PUVA Therapy; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014466:Ultraviolet Rays; D014820:Vitiligo / Q000188:drug therapy* / Q000473:pathology
D008730:Methoxsalen